ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Or

Kahn Swick & Foti, LLC (KSF) reminds investors of a pending securities class action lawsuit against Organon & Co. (OGN) for the Class Period of October 31, 2024, to April 30, 2025. The lawsuit alleges Organon and its executives failed to disclose material information, specifically resetting the quarterly dividend from $0.28 to $0.02 on March 10, 2025, which contradicted prior assurances regarding dividend commitment and capital allocation strategy. This announcement caused OGN shares to fall over 27%, from $12.93 to $9.45, on May 1, 2025. Investors who purchased during the Class Period have until July 22, 2025, to file lead plaintiff applications.

Analysis

Organon & Co. (OGN) is facing a significant legal challenge in the form of a securities class action lawsuit, which alleges that the company and its executives misled investors between October 2024 and April 2025. The core of the complaint is a stark reversal in the company's capital return policy. On March 10, 2025, management announced a drastic 93% cut to the quarterly dividend, reducing it from $0.28 to $0.02 per share. This action directly contradicted prior management assurances that the dividend was a "number one priority," severely damaging leadership credibility. The market's reaction, as cited in the lawsuit, was severe, with the company's share price collapsing over 27% from $12.93 on April 30, 2025, to $9.45 on May 1, 2025. This event introduces a substantial legal and reputational overhang for OGN, calling into question the reliability of its financial guidance and corporate governance.

Key Decisions for Investors

• Investors should re-evaluate Organon's investment thesis, as the dividend cut from $0.28 to $0.02 fundamentally alters the stock's profile for income-oriented portfolios and signals potential capital allocation pressures.
• Factor in a heightened risk premium for OGN shares due to the ongoing litigation and the significant impairment of management's credibility, which could lead to sustained stock price volatility and negative sentiment.
• Closely monitor developments in the 'Hauser V. Organon & Co.' class action lawsuit, as any rulings or settlement discussions will be material catalysts for the stock.